Furthermore, AR expression is variable in different subtypes of breast cancer, and high AR expression was reported in about 75% of HR+ cases, 50–60% of HER2+ cases, and 20–40% of TNBC cases, respectively (19). Here, ERBB2 is linked to breast cancer.